Comparative Pharmacology
Head-to-head clinical analysis: PIPERAZINE CITRATE versus STROMECTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERAZINE CITRATE versus STROMECTOL.
PIPERAZINE CITRATE vs STROMECTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic